Paloma Giangrande Email & Phone Number

Boston, Ma, Us

Cambridge, Massachusetts, United States; Cambridge, Uk; Tel Aviv, Israel

As CTO at Eleven Therapeutics, I will drive the strategic direction for the company's core xRNA technologies and platforms (TERA and DELiveri) with the goal to integrate these cutting-edge technologies into therapeutic applications.

Barcelona, Spain

Cambridge, Massachusetts, United States

• Oversaw Platform Discovery programs and projects• Lead Wave’s first RNA editing program, alpha 1 antitrypsin deficiency (AATD) from discovery into preclinical and clinical development and successfully completed CTA submission• Managed a cross-functional and interdisciplinary team of scientists conducting discovery/preclinical research on ASOs, RNA editing oligonucleotides, and dsRNA oligonucleotide-based drugs for various liver indications• Engaged and managed external efforts with industry partners, CROs, and/or academic collaborators.• Partnered in due diligence team with Business Development and External Innovation/Opportunity Units for identification and assessment of external platforms and pipeline opportunities in hepatic and extra-hepatic indications • Member of GSK-Wave Joint Development Committee for AATD Program• Established a strong network with KOLs in the field of hepatic, immune, and metabolic rare diseases.

500 Technology Square, Cambridge, Ma

• Managed a cross-functional and interdisciplinary team of scientists conducting mRNA-based preclinical research for monogenic, metabolic rare diseases.• Engaged and managed external efforts with CROs and/or academic collaborators.• Established a strong network with KOLs in the field of hepatic, metabolic rare diseases.• Partnered in due diligence team with Business Development and External Innovation/Opportunity Units for Identification and assessment of external platform and pipeline opportunities in monogenic, metabolic rare diseases space.• Achieved Lead Opt/Candidate goals for several rare disease programs. Advanced rare disease targets (GSD1a) from discovery into development phase and successfully completed IND submission.

Iowa City, Iowa, United States

During my tenure at the University of Iowa Hospital and Clinics, I developed synthetic targeted RNA reagents (aptamers) to proteins involved in disease (ex. receptors expressed on the surface of target-cells or soluble proteins secreted in blood) with SELEX (Systematic Evolution of Ligands by EXponential Enrichment) for 1) intervening therapeutically, 2) delivering therapeutic molecules (e.g. siRNAs, anti-miRs, drugs/toxins) into specific cell types, 3) diagnostics, and 4) acquiring mechanistic insights into a disease state.

Iowa City, Iowa, United States